Pancreatic cancer is one of the most rapidly fatal malignancies with a 5-year survival rate below 5%. The long-term survival is poor also for early diagnosed patients treated with resection surgery ([@bib19]). In Europe, it was estimated in a prediction model that in the year 2012 there would be 75 000--80 000 deaths from pancreatic cancer, which is the fourth most common cause of cancer-associated death for both men and women ([@bib24]). The incidence of pancreatic cancer is higher in the Nordic countries and Central Europe than in other parts of the world ([@bib5]).

Tobacco smoking is a well-established risk factor for pancreatic cancer ([@bib18]), and a similar magnitude of excess risk as smoking was found among the users of Scandinavian snus (moist snuff) ([@bib4]; [@bib23]). Besides, accumulating evidence consistently shows that old age, male sex, diabetes mellitus, hereditary pancreatitis, chronic pancreatitis and family history are positively associated with this carcinoma ([@bib29]). Albeit the biological mechanism is unclear, recent epidemiological studies indicated that some infections, such as exposure to *Helicobacter pylori* ([@bib38]), poor oral health ([@bib27]), hepatitis C virus (HCV) ([@bib14]; [@bib13]) or hepatitis B virus (HBV) ([@bib14]; [@bib17]; [@bib40], [@bib41]) might be associated with pancreatic cancer risk.

Globally, ∼170 million people are chronically infected with HCV ([@bib42]) and an estimated 350 million with HBV ([@bib8]). The prevalence rates of HCV and HBV infection vary widely in the world, and Sweden is a low endemic country with an estimated 0.5% of the population infected with HCV ([@bib10]) and even lower rate for HBV infection. Both chronic HCV and HBV infections are main causes of hepatocellular carcinoma (HCC). Previous findings demonstrated that HBV may replicate within the pancreas ([@bib33]; [@bib45]) and that HCV could be associated with pancreatitis ([@bib1]; [@bib36]). Some studies support that HCV and HBV may have a role in the development of pancreatic cancer, but the evidence is far from conclusive ([@bib14]; [@bib13]; [@bib17]; [@bib40], [@bib41]), and more studies are needed. Towards this end, we utilised Swedish population-based nationwide registers, with documentation of all diagnosed HCV- and HBV-infected individuals in Sweden, to explore the association of HCV or HBV infection and the risk of pancreatic cancer.

Materials and methods
=====================

Study population
----------------

The HCV and HBV cohorts have been described in detail in previous studies ([@bib12]; [@bib16]). Briefly, we identified all HCV and HBV infection notifications in Sweden from 1990 to the end of 2006, based on the records in the national surveillance database at the Swedish Institute for Infectious Disease Control (SMI), to generate our study cohorts. In Sweden, it is mandatory to report all diagnosed HCV and HBV infections to SMI since 1990 and 1969, respectively, and the notifications are delivered in parallel by the diagnosing laboratory and clinician and merged in the surveillance database using the personal identification number. The laboratory reports for HCV are based on positive HCV-RNA or anti-HCV test (verified with immunoblot, HCV-core antigen, or HCV-RNA analyses) and for HBV on positive HBsAg or HBV-DNA. The clinical reports contain information such as probable route of transmission and for HBV infection also information about acute or chronic infection based on clinical information and medical history.

After excluding subjects with multiple notifications, erroneous documentation, incomplete personal follow-up data, as well as those with acute HBV infection (*N*=2050), and those reported to both the HCV and the HBV register (*N*=3556) to exclude coinfection, there were 39 442 subjects with HCV infection forming the HCV cohort and 11 511 individuals with chronic HBV infection in the HBV cohort.

A five times larger reference population was produced from the Population Register at Statistics Sweden (1 : 5 matching). For each HCV- or HBV-infected subject another five individuals who were never diagnosed with a HCV or HBV infection were randomly selected from the general population matched on year of birth, sex and county of residence in Sweden. This procedure formed a HCV reference cohort of 197 208 individuals and a chronic HBV reference cohort of 57 554 subjects. Each individual in the noninfected reference cohorts was assigned the same 'study entry\' date as their matched infected individual, that is, the HCV or HBV notification date.

Linkage to other registers
--------------------------

The national registration number (NRN) is a unique personal identification number allocated to every Swedish resident. Via the NRNs, our cohort members were followed by cross linkages through Swedish registers, including the Population Register, Cause of Death Register, Cancer Register and the Inpatient Register, to obtain information on date of emigration, date and cause of death, any malignancies and hospital admissions for certain medical conditions.

Pancreatic cancer, as our main outcome, was ascertained from the Cancer Register (*International Classification of Disease* ICD-7: 157) for the principal analyses, but also from the Cause of Death Register (ICD-9: 157; ICD-10: C25) for some additional analyses.

From the Inpatient register hospitalisations with the discharge diagnoses of chronic obstructive pulmonary disease, diabetes mellitus, chronic pancreatitis and diagnoses related to alcohol abuse were identified (for ICD-codes, see [Appendix Table A1](#app1){ref-type="app"}). These medical conditions were considered as potential confounders or related to a confounder and therefore identified and adjusted for in some of the analyses.

For additional analyses also acute pancreatitis was identified from the Inpatient Register, and to further study the impact of smoking all incident lung cancers in the cohorts were ascertained from the Cancer Register (ICD-codes in [Appendix Table A1](#app1){ref-type="app"}).

Follow-up
---------

The individuals in the cohorts were followed from the entry date, either their HCV/HBV notification date or the corresponding assigned study entry date (noninfected reference population), until the date of first primary cancer diagnosis, emigration, death or the end of follow-up (31 December 2008), whichever came first.

To minimise the potential influence of selection bias, the first 6 months of follow-up for each patient were excluded in all final analyses. This lag time of 6 months was based on modelling the hazard after inclusion in the cohort using a restricted cubic spline model ([@bib37]).

Statistical analyses
--------------------

In the first statistical analysis, the risk for pancreatic cancer in the HCV cohort and in the HBV cohort was compared with the risk in the general population. This was measured as the Standardized Incidence Ratio (SIR), which is the ratio of the observed number of pancreatic cancer cases compared with the expected case number. For each cohort, the expected numbers were calculated from the observed person-time in each 5-year age group by sex and the corresponding Swedish population incidence rates. Thus, in the SIR calculation, age of follow-up, sex and calendar year were inherently adjusted. Assuming that the number of observed pancreatic cancer cases followed a Poisson distribution, 95% confidence intervals (CIs) were calculated according to the Max method ([@bib21]). Stratified analyses were performed by sex, infection duration, period and year of birth (before/after 1960). On the basis of an earlier developed model, duration of HCV infection at the time of notification was estimated according to age, suspected route of transmission and the epidemiology of HCV transmission in Sweden ([@bib11]).

In the second statistical analysis, to further evaluate the association, we utilised the Cox proportional hazards regression model to estimate hazard ratios (HRs) and the corresponding 95% CIs. Pancreatic cancer risk in the HCV cohort and in the HBV cohort was compared with pancreatic cancer risk in the corresponding noninfected reference cohort. In these cohorts, the noninfected individuals were matched to the HCV- or HBV-infected patients by birth year, sex and county of Sweden; therefore, these variables were inherently adjusted in the models. Furthermore, adjustments for other potential confounders were applied in the Cox model, including hospitalisations for chronic obstructive pulmonary disease, diabetes mellitus, chronic pancreatitis and diagnoses related to alcohol abuse. However, concerning that diabetes mellitus or chronic pancreatitis might be consequences of pancreatic cancer, we ignored diabetes mellitus or chronic pancreatitis diagnoses within 5 years before pancreatic cancer diagnosis. Finally, we conducted an additional analysis stratified by sex.

Acute pancreatitis might be a complication to interferon therapy for HCV infection, and pancreatitis is reported to be a risk factor for pancreatic cancer. To exclude the possibility of iatrogenic risk, additional Cox regression analyses were made after exclusion of all patients who ever hospitalised for acute and/or chronic pancreatitis (in the HCV cohort: *n*=1387; in the HCV reference cohort: *n*=1491).

The Swedish Cancer Register does not include the Death Certificate Only cases, thus some pancreatic cancers might be missed by only using the Cancer Register ([@bib22]). Therefore, we further performed a Cox regression analysis including pancreatic cancer cases ascertained from the Cancer register and the Cause of Death Register.

In order to estimate the potential influence of smoking, similar analyses (SIR, HR) were conducted for lung cancer in parallel.

The R language for statistical computing ([@bib31]) was used for both data preparation and the statistical analyses. For the statistical analyses, the R-package 'survival\' ([@bib35]) was used together with Lexis objects (Martyn [@bib25]) in the 'Epi\' R-package ([@bib6]).

Ethical approval
----------------

The study was approved by the Regional Ethical Review Board in Stockholm, Sweden. To ensure the data confidentiality, the personal identification numbers were deleted after the record linkage and before the analysis.

Results
=======

Baseline characteristics of the HCV and HBV cohorts are presented in [Table 1](#tbl1){ref-type="table"}. In the HCV and chronic HBV cohorts the mean follow-up time were 9.1 and 9.4 years, with a total of 360 154 and 107 986 person-years at risk, respectively. There was a clear male dominance in the HCV cohort, and median age at entry into the HCV or HBV cohorts (notification date) was 38 and 31 years, respectively. A marked difference between cohorts was observed regarding the aspect of country of origin; HCV-infected individuals were more likely from Nordic countries, but persons with chronic HBV infection were often immigrants from non-Nordic countries.

Hepatitis C virus cohort
------------------------

In the HCV cohort, there were 34 pancreatic cancer cases observed during 340 819 person-years of follow-up (first 6 months of follow-up excluded), whereas 16.5 were expected, yielding a statistically significant increased risk of pancreatic cancer (SIR: 2.1; 95% CI: 1.4, 2.9). The SIR did not alter substantially across sex or estimated duration of HCV infection ([Table 2](#tbl2){ref-type="table"}). The majority of cases were among the patients who were born before 1960.

From the Cox regression model, an ∼90% excessive risk for pancreatic cancer (HR 1.9; 95% CI: 1.3, 2.7) was observed after adjustment for age, sex and county of residence, which is similar to the result from the SIR analysis. This excess risk diminished somewhat but remained statistically significant after further adjustment for potential confounders (HR 1.6; 95% CI: 1.04, 2.4). The results did not vary markedly when stratified by sex ([Table 3](#tbl3){ref-type="table"}). In the additional analyses, excluding all individuals ever hospitalised with acute and/or chronic pancreatitis, the results did not alter notably (data not shown).

In the HCV cohort, the SIR for lung cancer was 2.3 (95% CI: 1.9, 2.7) and the HR for lung cancer was 2.2 (95% CI: 1.8, 2.7), decreasing to 1.6 (95% CI: 1.3, 2.1) after adjustment for the potential confounders used in the pancreatic cancer analyses.

Chronic HBV cohort
------------------

A total of five pancreatic cancer cases were found during 102 295 person-years of follow-up (first 6 months excluded), whereas 3.5 were expected. Compared with the age- and sex-matched Swedish general population, a 40% excess risk of pancreatic cancer was found in the chronic HBV cohort (SIR: 1.4; 95% CI: 0.5, 3.3), but without statistical significance. Because of the small number of pancreatic cancer cases, there was not enough power for additional stratified analyses ([Table 4](#tbl4){ref-type="table"}).

The Cox regression model revealed similar results as the SIR analysis. The point estimates were somewhat higher (HR=2.0 from the model adjusted for only matching factors and HR=1.8 from the fully adjusted model), but still statistically non-significant ([Table 5](#tbl5){ref-type="table"}). The SIR for lung cancer in the chronic HBV infection cohort was 1.7 (95% CI: 1.1, 2.5).

Additional analyses
-------------------

To rule out the impact of pancreatic cancer cases missing in the Cancer Registry, additional analyses (Cox regression model) were performed including both Cancer Register and Death Certificate Only pancreatic cancers (HCV cohort: *n*=77; chronic HBV cohort: *n*=20). The main results did not alter appreciably (HR for HCV infection: 1.9, 95% CI: 1.4, 2.6; other data not shown).

Discussion
==========

This population-based large cohort study revealed a doubled risk of pancreatic cancer among HCV-infected patients compared with the Swedish general population. The excess risk was persistent across strata by sex or duration of infection. Although further adjustment for potential confounders, i.e., chronic obstructive pulmonary disease (related to smoking), diabetes mellitus, chronic pancreatitis and alcohol-related disease, resulted in an attenuated relative risk, this finding still supports the hypothesis that HCV infection might be associated with an increased risk of pancreatic cancer. Besides, the result indicated a moderate excessive risk of pancreatic cancer among HBV-infected patients according to different statistical approaches, but the size of the study cohort and the observed number of cancers were too small to draw a sound conclusion. Pancreatic cancer is more common in older age groups, and the small number of pancreatic cancers among the HBV cohort was probably an effect of the relatively young cohort, concordant with the epidemiology of chronic hepatitis B in Sweden.

The strengths of this register-based study include population-based cohort design, relatively large sample size, independently collected data on documentation of HCV/HBV notifications and pancreatic cancer occurrence and high completeness of follow-up. However, some limitations need to be discussed.

Tobacco use is an established risk factor and cigarette smokers have a doubled risk for pancreatic cancer ([@bib5]). In this study, it was impossible to identify smokers but possible to identify subjects diagnosed with chronic obstructive pulmonary disease (a smoking-related disease). Besides, diabetes mellitus, chronic pancreatitis and heavy alcohol consumption are possible risk factors for pancreatic cancer ([@bib43]; [@bib36]; [@bib3]) that might bias the association between HCV infection and pancreatic cancer risk. To allay these concerns, we adjusted for chronic obstructive pulmonary disease, diabetes mellitus, chronic pancreatitis as well as alcohol-related disease strongly correlated to heavy alcohol consumption in the Cox regression model. Although slightly attenuated, the HRs for pancreatic cancer did not alter remarkably after adjustment for these potential confounding factors. In order to get further insight into potential effects of smoking, the SIR and HR for lung cancer were calculated. A doubled risk of lung cancer in the HCV cohort indicated that smoking was more common than in the general population. The HR for lung cancer decreased to 1.6 after adjustment for the potential confounders also used in the pancreatic cancer analyses, strengthening the use of these diagnoses as surrogate markers for smoking. After adjustment the HRs were attenuated but still increased at the similar magnitude for pancreatic cancer and lung cancer, indicating that smoking was not the only explanation of the increased risk for pancreatic cancer in the HCV cohort. If this finding was explained only by smoking the HR of lung cancer in the HCV cohort probably should have been higher, as in previous studies the relative risk of lung cancer was ∼10 among smokers compared with non-smokers ([@bib30]), whereas that for pancreatic cancer was around two-fold ([@bib5]). Furthermore, based on Walker\'s finding ([@bib39]), the confounding effect size is usually rather small even when both the exposure-covariate relationship and confounder-disease relationship are strong. For instance, in order to completely bias the exposure effect of 1.4 by a pure confounding of smoking, it requires that both the association between smoking and HCV/HBV infection as well as smoking and pancreatic cancer are larger than 3.

Acute pancreatitis could possibly be a complication of interferon therapy ([@bib7]) and might act as a potential mediator in the pathway between HCV infection and pancreatic cancer. To exclude the possibility of iatrogenic risk, additional analyses were performed excluding all individuals ever hospitalised with pancreatitis (acute and chronic), but the results did not alter notably.

Another potential risk factor for pancreatic cancer is the use of Scandinavian snus ([@bib4]; [@bib23]), which is a common habit in Sweden; Statistics Sweden reported in 2012 that, irrespective of socioeconomic status, 20--25% of men were snus-users. We have no information about the prevalence of snus-users in the HCV or HBV cohort.

In the relatively young HBV cohort, the sample size and the number of observed cancers were too small to draw a sound conclusion, not to mention further stratified analyses. An issue that needs to be addressed is that the majority of HBV-infected patients originated from non-Nordic countries, 37% from former Yugoslavia and 32% from Asia. This probably resulted in an underestimation of the relative pancreatic cancer risk in this cohort given the fact that pancreatic cancer incidence has been reported higher among Swedes than immigrants ([@bib28]). However, we were unable to match the HBV-infected patients and the reference population on their country of birth.

The parallel (laboratory and clinician) notification system of HCV/HBV infections in Sweden has a high coverage of those with a diagnosed infection; it is estimated that about 75--80% of HCV infections are diagnosed, but there still remain unknown infections, not yet diagnosed or documented. In addition, a small portion of the reported patients could have a resolved infection, spontaneously or by treatment, this could (probably insignificant) lower the risk in the HCV and HBV cohort.

The number of unidentified HCV/HBV-coinfected individuals is probably low in the studied cohorts. However, in the HCV cohort there could be some patients who were never diagnosed with hepatitis B but have serologic markers of a past HBV infection. In these patients we cannot exclude the possibility of occult hepatitis B.

The biological mechanism of the association between HCV and pancreatic cancer is unclear. However, virtually, the pancreas and liver share the common blood vessels and ducts, and prior evidence demonstrated that the pancreas is a remote location for hepatitis virus inhabitation and replication ([@bib14]). HCV infection is associated with type 2 diabetes, which is both a risk factor and might be a consequence of pancreatic cancer ([@bib26]; [@bib32]). Besides, previous studies reported that subclinical/acute pancreatitis ([@bib20]) and hyperlipasemia ([@bib44]) may be extrahepatic manifestations of HCV infection. In addition, pancreatic involvement was observed among patients who suffered from chronic hepatitis infection, resulting in mild pancreatic damage accompanied with increased serum levels of pancreatic enzyme ([@bib34]; [@bib20]). Immune response may lead to chronic inflammation in the targeted organs after long time persistent infection with HCV. Therefore, hepatitis C virus conceivably serves as a biological agent that may indirectly have a role in inflammation-associated pancreatic carcinogenesis. Although still unclear to what extent chronic inflammation contributes to pancreatic cancer development, it is postulated that HCV can induce inflammatory microenvironment with high concentration of growth factors and cytokines. This may exert effects by accumulating alterations in driver genes and promoting cancer cell growth and proliferation. To date, very few epidemiologic studies have explored the association between HCV and pancreatic cancer. In the US veterans cohort study ([@bib13]), a significant association between HCV and pancreatic cancer was first found but was attenuated after adjusting for alcohol consumption, pancreatitis and some other potential confounders. In a case--control study, [@bib14] found that the prevalence of HCV antibodies was not significantly higher among patients with pancreatic cancer (1.5%) than controls (1%). In our cohort study we found a doubled risk for pancreatic cancer in the HCV cohort, somewhat attenuated after adjustment for confounders but still statistically significant, indicating that HCV may have a role in the pancreatic carcinogenesis.

The role of HBV in carcinogenesis is not totally understood. Earlier studies proposed that HBV may replicate in the pancreas, based on the facts of detection of HBsAg in pancreatic juice ([@bib15]), the detection of HBsAg and HBV core antigen in the pancreas acinar cells ([@bib45]), and verification of HBV-DNA integration in pancreatic tissue ([@bib9]). As mentioned, it has been hypothesised that long-term chronic HBV infection, concurrent with damage of pancreatic epithelial cells, results in an inflammatory response and consequently has a role in pancreatic cancer development ([@bib34]).

Some epidemiologic studies have investigated the association between HBV infection and pancreatic cancer risk. In a case--control study, [@bib14] reported a significantly increased prevalence of past exposure to HBV, but not current or chronic infection, in patients with pancreatic cancer compared with controls. In contrast, the REVEAL-HBV cohort study and a recent Chinese case--control study suggested that an increased risk of pancreatic cancer was associated with chronic HBV infection ([@bib17]; [@bib2]). In a recent meta-analysis, it was reported that inactive HBsAg carrier status and possible occult HBV infection may elevate the risk of pancreatic cancer ([@bib41]). In our study, point estimates favoured a positive association between HBV infection and pancreatic cancer risk, but due to a limited study power none of the observed associations were statistically significant.

In conclusion, this nationwide population-based cohort study demonstrated an increased risk of pancreatic cancer among HCV-infected individuals, although this excess risk was attenuated but still statistically significant after adjustment for other potential risk factors. Our results support the hypothesis that HCV infection might be associated with an increased risk of pancreatic cancer, but further studies, with more complete information about other potential confounding factors, are needed to verify the association and to explore the causality.
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###### Characteristics of the study population, the chronic hepatitis B virus (HBV) infection and the hepatitis C virus (HCV) infection cohorts

                                                       **Chronic HBV cohort**[a](#t1-fn1){ref-type="fn"}, ***N*** **(%)**   **HCV cohort**[b](#t1-fn2){ref-type="fn"}, ***N*** **(%)**
  --------------------------------------------------- -------------------------------------------------------------------- ------------------------------------------------------------
  Number in cohort                                                                   11 511                                                           39,442
  Deceased                                                                         738 (6.4)                                                       7872 (20.0)
  Emigrated                                                                        780 (6.8)                                                        1326 (3.4)
  Person-years accumulated during follow-up                                         107 986                                                          360 154
  Mean follow-up time, years                                                          9.4                                                              9.1
  Male sex %                                                                      6117 (53.1)                                                     27 024 (68.5)
  Median age at HBV/HCV notification (male, female)                               31 (33, 29)                                                      38 (38, 37)
  Year of birth, median (range)                                                1967 (1906, 2006)                                                1958 (1898, 2006)
  **Country of origin**                                                                                                    
  Nordic countries                                                                1779 (15.5)                                                     35 033 (88.8)
  Non-Nordic European countries                                                   3166 (27.5)                                                       2035 (5.2)
  Other                                                                           6482 (56.3)                                                       2305 (5.8)
  **Suspected route of virus transmission**                                                                                
  Intravenous drug use                                                             178 (1.5)                                                      21 941 (55.6)
  Blood/blood products                                                             179 (1.6)                                                        2423 (6.1)
  Sexual contact                                                                   334 (2.9)                                                        891 (2.3)
  Nosocomial transmission                                                           38 (0.3)                                                        130 (0.3)
  Mother-child                                                                     762 (6.6)                                                         92 (0.2)
  Other                                                                           2744 (23.8)                                                       848 (2.1)
  Unknown or missing                                                              7276 (63.2)                                                     13 117 (33.3)

Includes individuals notified with chronic HBV infection between 1990 and 2006.

Includes individuals notified with HCV infection between 1990 and 2006.

###### Standardized Incidence Ratio (SIR) for pancreatic cancer among 39 442 individuals infected with hepatitis C virus (HCV) compared with the general population

                                                                               **Pancreatic cancer**               
  --------------------------------------------------------------------------- ----------------------- ------ ----- -------------
  **Lag period after HCV notification**                                                                            
  ⩽6 Months                                                                              4             0.8    5.3   (1.4, 13.5)
  \>6 Months                                                                            34             16.5   2.1   (1.4, 2.9)
  **Sex-stratified analysis**[c](#t2-fn4){ref-type="fn"}                                                           
  Men                                                                                   23             11.5   2.0   (1.3, 3.0)
  Women                                                                                 11             5.0    2.2   (1.1, 3.9)
  **HCV duration**[c](#t2-fn4){ref-type="fn"}^,^[d](#t2-fn5){ref-type="fn"}                                        
  ⩽20 Years                                                                             10             5.4    1.9   (0.9, 3.4)
  \> 20 Years                                                                           24             11.1   2.2   (1.4, 3.2)
  **Year of birth**[c](#t2-fn4){ref-type="fn"}                                                                     
  Before 1960                                                                           31             15.5   2.0   (1.4, 2.8)
  From 1960                                                                              3             1.0    3.0   (0.6, 8.8)

Abbreviation: CI=confidence interval.

Observed number of pancreatic cancer cases.

Expected number of pancreatic cancer cases.

Excluding cases and observation-time during the first 6 months after HCV notification.

Estimated duration of HCV infection.

###### Hazard ratios of pancreatic cancer associated with hepatitis C virus (HCV) infection

                                                                            **Pancreatic cancer**        
  ------------------------------------------------------------------------ ----------------------- ----- -------------
  **Total**                                                                          154                        
  Non-HCV infection                                                                  120            1.0         
  HCV infection[b](#t3-fn3){ref-type="fn"}                                           34             1.9   (1.3, 2.7)
  HCV infection[b](#t3-fn3){ref-type="fn"}^,^[c](#t3-fn4){ref-type="fn"}             34             1.6   (1.04, 2.4)
  **Sex**[a](#t3-fn2){ref-type="fn"}                                                                     
  Men, total                                                                         99                         
  Non-HCV infection                                                                  76             1.0         
  HCV infection[b](#t3-fn3){ref-type="fn"}                                           23             2.0   (1.2, 3.2)
  HCV infection[b](#t3-fn3){ref-type="fn"}^,^[c](#t3-fn4){ref-type="fn"}             23             1.7   (1.02, 3.0)
  **Women, total**                                                                   55                         
  Non-HCV infection                                                                  44             1.0         
  HCV infection[b](#t3-fn3){ref-type="fn"}                                           11             1.7   (0.9, 3.2)
  HCV infection[b](#t3-fn3){ref-type="fn"}^,^[c](#t3-fn4){ref-type="fn"}             11             1.4   (0.7, 2.9)

Abbreviation: CI=confidence interval.

First 6 months of follow-up after HCV notification were excluded.

Inherently adjusted for birth year, sex and county of residence in the model.

Adjusted for chronic obstructive pulmonary disease, diabetes mellitus, chronic pancreatitis and alcohol-related diseases.

###### Standardized Incidence Ratio (SIR) for pancreatic cancer among 11 511 individuals with chronic hepatitis B virus (HBV) infection compared with the general population

                                                                 **Pancreatic cancer**                                                     
  -------------------------------------------------------- ---------------------------------- ---------------------------------- --------- -------------
                                                            **O**[a](#t4-fn2){ref-type="fn"}   **E**[b](#t4-fn3){ref-type="fn"}   **SIR**   **95% CI**
  **Lag period after HBV notification**                                                                                                    
  ⩽6 Months                                                                3                                 0.2                   19.5     (4.0, 57.1)
  \>6 Months                                                               5                                 3.5                    1.4     (0.5, 3.3)
  **Sex-stratified analysis**[c](#t4-fn4){ref-type="fn"}                                                                                   
  Men                                                                      4                                 2.2                    1.8     (0.5, 4.6)
  Women                                                                    1                                 1.3                    0.8     (0.02, 4.3)

Abbreviation: CI=confidence interval.

Observed number of pancreatic cancer cases.

Expected number of pancreatic cancer cases.

Excluding cases and person-time during the first 6 months after chronic HBV notification.

###### Hazard ratios (HRs) of pancreatic cancer associated with chronic hepatitis B virus (HBV) infection[a](#t5-fn1){ref-type="fn"}

                                                                           **Pancreatic cancer**            
  ------------------------------------------------------------------------ ----------------------- -------- ------------
                                                                           **Cases**               **HR**   **95% CI**
  **Total**                                                                21                                
  Non-HBV infection                                                        16                      1.00      
  HBV infection[b](#t5-fn2){ref-type="fn"}                                 5                       2.0      (0.7, 5.3)
  HBV infection[b](#t5-fn2){ref-type="fn"}^,^[c](#t5-fn3){ref-type="fn"}   5                       1.8      (0.7, 5.1)

Abbreviation: CI=confidence interval.

First 6 months of follow-up after HBV notification were excluded.

Inherently adjusted for birth year, sex and county of residence in the model.

Adjusted for chronic obstructive pulmonary disease, diabetes mellitus, chronic pancreatitis and alcohol-related diseases.

###### Covarieties definitions by ICD-7 to ICD-10 codes

  --------------------------------------- ----------------- ----------------- ---------------------- -------------------------
                                           **ICD-7 codes**   **ICD-8 codes**     **ICD-9 codes**         **ICD-10 codes**
  Pancreatic cancer                          157^**a**^            157              157^**b**^              C25^**b**^
  Lung cancer                               162.1^**a**^           162              162^**b**^              C34^**b**^
  Chronic obstructive pulmonary disease                            491                 491                      J44
  Diabetes mellitus                                                250                 250            E10, E11, E12, E13, E14
  Chronic pancreatitis                                       577.10, 577.19            577B                     K86
  Acute pancreatitis                                              577.0                577A                     K85
  Alcohol abuse                                                 291, 303       291, 303, 305A, V79B          F10, T51
  --------------------------------------- ----------------- ----------------- ---------------------- -------------------------

Abbreviation: ICD=International Classification of Disease.

^**a**^Use Cancer Register for identification.

^**b**^Use Cause of Death Register for identification.
